Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Induction of labor versus expectant management in women with preterm prelabor rupture of membranes between 34 and 37 weeks: a randomized controlled trial.

van der Ham DP, Vijgen SM, Nijhuis JG, van Beek JJ, Opmeer BC, Mulder AL, Moonen R, Groenewout M, van Pampus MG, Mantel GD, Bloemenkamp KW, van Wijngaarden WJ, Sikkema M, Haak MC, Pernet PJ, Porath M, Molkenboer JF, Kuppens S, Kwee A, Kars ME, Woiski M, Weinans MJ, Wildschut HI, Akerboom BM, Mol BW, Willekes C; PPROMEXIL trial group..

PLoS Med. 2012;9(4):e1001208. doi: 10.1371/journal.pmed.1001208. Epub 2012 Apr 24.

2.

17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.

Lim AC, Schuit E, Bloemenkamp K, Bernardus RE, Duvekot JJ, Erwich JJ, van Eyck J, Groenwold RH, Hasaart TH, Hummel P, Kars MM, Kwee A, van Oirschot CM, van Pampus MG, Papatsonis D, Porath MM, Spaanderman ME, Willekes C, Wilpshaar J, Mol BW, Bruinse HW.

Obstet Gynecol. 2011 Sep;118(3):513-20. doi: 10.1097/AOG.0b013e31822ad6aa.

PMID:
21860279
3.

Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2).

Eriksson BI, Turpie AG, Lassen MR, Prins MH, Agnelli G, Kälebo P, Wetherill G, Wilpshaar JW, Meems L; ONYX-2 STUDY GROUP..

J Thromb Haemost. 2010 Apr;8(4):714-21. doi: 10.1111/j.1538-7836.2010.03748.x. Epub 2010 Jan 17.

4.

Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia.

Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, Wiklund O, Southworth H, Pears J, Wilpshaar JW; Rosuvastatin Investigators Group..

Am Heart J. 2002 Dec;144(6):1044-51.

PMID:
12486429
5.

Magnetic resonance imaging of fetal bone marrow for quantitative definition of the human fetal stem cell compartment.

Wilpshaar J, Joekes EC, Lim FT, Van Leeuwen GA, Van den Boogaard PJ, Kanhai HH, Willemze R, Falkenburg JH.

Blood. 2002 Jul 15;100(2):451-7.

6.

Engraftment potential of human fetal hematopoietic cells in NOD/SCID mice is not restricted to mitotically quiescent cells.

Wilpshaar J, Bhatia M, Kanhai HH, Breese R, Heilman DK, Johnson CS, Falkenburg JH, Srour EF.

Blood. 2002 Jul 1;100(1):120-7.

7.

Engraftment potential into NOD/SCID mice of CD34+ cells derived from human fetal liver as compared to fetal bone marrow.

Wilpshaar J, Noort WA, Kanhai HH, Willemze R, Falkenburg JH.

Haematologica. 2001 Oct;86(10):1021-8.

8.

Similar myeloid recovery despite superior overall engraftment in NOD/SCID mice after transplantation of human CD34(+) cells from umbilical cord blood as compared to adult sources.

Noort WA, Wilpshaar J, Hertogh CD, Rad M, Lurvink EG, van Luxemburg-Heijs SA, Zwinderman K, Verwey RA, Willemze R, Falkenburg JH.

Bone Marrow Transplant. 2001 Jul;28(2):163-71.

9.

Fetal hematopoiesis during first and second trimester of pregnancy: relevance for in utero stem cell transplantation.

Wilpshaar J, Kanhai HH, Scherjon S, Falkenburg JH.

Ernst Schering Res Found Workshop. 2001;(33):173-86. Review. No abstract available.

PMID:
11105260
10.

Similar repopulating capacity of mitotically active and resting umbilical cord blood CD34(+) cells in NOD/SCID mice.

Wilpshaar J, Falkenburg JH, Tong X, Noort WA, Breese R, Heilman D, Kanhai H, Orschell-Traycoff CM, Srour EF.

Blood. 2000 Sep 15;96(6):2100-7.

11.

Multicenter study of the efficacy, cycle control and tolerability of a phasic desogestrel-containing oral contraceptive.

Ferguson H, Vree ML, Wilpshaar J, Eskes TK.

Eur J Contracept Reprod Health Care. 2000 Mar;5(1):35-45.

PMID:
10836661

Supplemental Content

Loading ...
Support Center